BlackRock, Inc. 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | PMV Pharmaceuticals, Inc. PMVP |
BlackRock Inc. BLK |
1,162,193 2.300% |
-2,067,604 (-64.02%) |
Filing |
| 2024-01-29 3:26 pm Sale |
2023-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
BlackRock Inc. BLK |
3,229,797 6.300% |
-1,447,231 (-30.94%) |
Filing |
| 2023-07-07 4:35 pm Purchase |
2023-06-30 | 13G | PMV Pharmaceuticals, Inc. PMVP |
BlackRock Inc. BLK |
4,677,028 10.200% |
1,225,661 (+35.51%) |
Filing |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
BlackRock Inc. BLK |
3,451,367 7.600% |
911,543 (+35.89%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
BlackRock Inc. BLK |
2,539,824 5.600% |
2,539,824 (New Position) |
Filing |